Students find mental health support from embedded counselors

8227

https://dornsife.usc.edu/news/stories/3825/embedded-counselors-mental-health-resource/
Story Headline and Deck – USC News *
Students can access tailored support from dedicated mental health professionals

Embedded counselors provide greater mental health assistance for USC Dornsife’s diverse community of young scholars.
Body Copy *
Balancing tough academic courses with the increased responsibilities that come with independence – all while maintaining a social life – can be a challenging struggle that impacts a student’s mental health.

Amid a growing culture of mental health assistance in the nation, many colleges and universities have implemented measures for students’ mental well-being, such as bringing in more psychologists and therapists to assist students. At the USC Dornsife College of Letters, Arts and Sciences, students seeking these treatments need look no further than their own academic departments, where counselors have been embedded to provide greater access to mental health care.

According to Emily Anderson, college dean of undergraduate education, the pandemic signaled a greater need for mental health assistance, which led to increased accessibility for therapy services.

“I stepped into my position right in the middle of the pandemic, and clearly a major need for students at that time was mental health wellness support, and the university in general was increasing those resources substantially,” she said.

Embedded mental health professionals focus on particular needs

Embedded counselors are therapists that remain specifically within a cultural community or program to better understand the population and their specific needs. Rather than attempting to understand the struggles of the entire student body, these counselors tailor solutions for the unique challenges that face certain populations. For instance, cultural programs such as Asian Pacific American Student Services, the Center for Black Cultural and Student Affairs and the LGBTQ+ Center have implemented this embedded model to meet the needs of students belonging to marginalized communities.

“[The embedded counselors] give us the chance to tailor the kind of emotional and mental support we provide to students, both in terms of individual interactions and often in terms of workshops, programming, you name it,” Anderson said.

Guru Shabd Khalsa, a clinical instructor of psychiatry and the behavioral sciences, serves as an embedded clinician for USC Dornsife. She appreciates the students’ varied passions.

“We love the variety of students and experience within Dornsife,” she said. “All the language and cultural studies mean to me that our students are interested in the people and world around them, and that connection and curiosity make for great interactions.”

Khalsa shared that USC Dornsife’s diverse population came with varied concerns, and encouraged students to reach out when they needed help.

“That being said, we’ve encountered some common concerns like anxiety, depression, struggling to adjust to life on campus and managing perfectionism and procrastination,” Khalsa said. “It’s important to remember that transitions are hard and can take time, we all deserve compassion no matter what situation we have found ourselves in, and asking for help is a sign of strength, not weakness.”

Students gain better access to mental health services

Summer Zapata, assistant director for academic embedded services and graduate student counseling, says the embedded model has been beneficial for counselors as well, allowing for more genuine relationships between the students and clinicians.

“I think the counselors have a lot of passion for working with these particular students and programs, and it allows them to get more personally connected with the faculty and staff and with the students in particular,” Zapata said.

Zapata also believes that the embedded counselors program has raised the visibility of mental health treatment at USC and allowed students to access services more easily and with less stigma.

“As clinicians, we work hard to fight against the stigma of therapy and mental health struggles,” Khalsa said. “Needing help or support does not mean there’s something wrong with you, and if you speak up and ask for help sooner, before things become a full-blown crisis, the process is so much better and effective.”

USC Dornsife currently has five embedded counselors that serve the diverse student population. Students can book an appointment with a therapist through USC’s mySHR portal.

The post Students find mental health support from embedded counselors appeared first on USC News.

Hear, hear! The power of sound

8096

https://dornsife.usc.edu/news/stories/3791/hear-hear/
Story Headline and Deck – USC News *
Hear, Hear!

Whether it takes the form of a rousing rock concert, a friendly greeting or the lulling buzz of cicadas on a summer evening, sound holds the power to energize us, to cheer us, to soothe us and — above all — to connect us.
Body Copy *
When Ludwig van Beethoven began losing his hearing as a young man in 1798, he blamed it on a fall, though modern researchers believe illness, lead poisoning or a middle ear deformity could have been factors. Whatever the cause, the hearing impairment did nothing to sweeten the acclaimed composer’s notoriously sour disposition, understandably contributing to his melancholy and ill temper.

Today, more than 200 years after the onset of Beethoven’s hearing problems, we know far more about the nature of sound and the causes of hearing loss. We also better understand how the brain comprehends language, and the power of music to affect brain activity.

But if we now have the means to protect against certain diseases that affect hearing, solutions to address the most common cause of hearing loss, aging, have been more challenging. The effects of aging on hearing can be slowed or partially ameliorated without biomedical devices, but they cannot be reversed — yet.

New hope for the deaf

USC Dornsife’s Charles McKenna, professor of chemistry, believes he, along with scientists at Harvard Medical School’s Massachusetts Eye and Ear Institute, may have discovered a drug to repair inner ear cells that are damaged not only from aging, but from prolonged exposure to noise. This drug has the potential to treat damaged areas without being washed away by the ear’s natural fluid — a crucial breakthrough.

McKenna explains that neural sensors turn the vibrations we perceive as sounds into electrical impulses that the brain can register and decipher. When these sensors are damaged, hearing loss and other issues occur.

“A nerve can send a signal to the brain that lets the brain say, ‘This is a Mozart composition’ or ‘This is someone speaking,'” McKenna says. “The theory is that if you could regenerate the neural sensors, you would restore hearing to those who have lost it. Though there are drugs that appear to have the ability to induce regeneration of these neural sensors, successfully deploying those drugs has been a tremendous challenge.”

First, the cochlea, the part of the inner ear where damaged cells are located, is bony, making it difficult for drugs to adhere to it. Second, even if a compound is shown to attach to the structure, the inner ear’s naturally occurring fluid tends to wash it away before it can work.

Based on encouraging findings from their latest study, McKenna says he and his colleagues are optimistic their compound will adhere to the cochlea long enough to be effective. With more research, they hope to prove its efficacy.

The Power of Music

While Beethoven struggled with hearing problems, his music, perhaps paradoxically, may help improve the brain functions of others.

Assal Habibi, head of the Brain & Music Lab at USC Dornsife’s Brain and Creativity Institute and associate professor (research) of psychology, explores how music and song affect brain activity using data collected through electroencephalography and neuroimaging. She and her colleagues have found that music can have several quantifiable benefits for the human brain, particularly in children. For example, playing music can help children hone their concentration skills.

“Music training helps with what is known as speech-in-noise perception — for example, when you’re in a noisy environment and someone is calling your name or saying something you need to hear,” Habibi says. “This is a crucial ability for children in a noisy classroom who need to be able to hear the teacher and tune out background noise.”

Music training has also been shown to help some children reach developmental milestones faster. If ongoing research can establish the connection, music training might be able to prevent the onset of certain behavioral and learning issues and lead to new therapies for children who struggle with them.

“One hypothesis is that if music can assist children in reaching developmental milestones faster, for example if they develop language skills earlier, they will be able to better express their feelings and communicate more
effectively,” Habibi says.

The Science of Language

While music therapy can help individuals sharpen their ability to discern the signal from the noise, linguistics is the discipline that deals with how we create and process the signal — speech itself.

Linguists specialize in the building blocks of language, or how sounds combine to create a word that is understood by different people, despite the fact that no two people will speak a word completely identically. Dani Byrd, professor of linguistics at USC Dornsife, examines how the vocal tract creates and combines these sounds in everyday speech, and how languages evolve to structure these sounds for encoding information.

“As a linguist I ask, ‘What are the rules that languages use to build their structures, to build their words and phrases? How do they differ from language to language?’ And I look at how and why we can understand these sounds as we do.”

Byrd says our complicated and incredibly nuanced sense of hearing mirrors a corresponding complexity in how we shape our words and sounds to convey meaning.

“The sensory cells of the inner ear are the most sensitive mechanoreceptor of the body. They have movements on a nanometer scale,” she says. “When air pressure fluctuations move your eardrum, that creates movement and an electrochemical cascade inside the inner ear.”

Our sense of hearing has the power to move us in a myriad ways. It also has the power to inspire wonder at its many — as yet — still unsolved mysteries: Why is it that we understand a gasp as a signal of surprise, or possibly fear? Why does the key of D minor often provoke feelings of sadness in one listener but not another? And how is it that our brain can take these vibrations of air and transform them into words, emotions
or messages?

“Isn’t it amazing,” says Byrd, “that these tiny fluctuations in air pressure can make you laugh or cry, can convey urgency, can make you fall in love?”

The post Hear, hear! The power of sound appeared first on USC News.

Can hormone replacement therapy protect the heart and brain after menopause?

8211 https://news.keckmedicine.org/can-hormone-replacement-therapy-protect-the-heart-and-brain-after-menopause/
Story Headline and Deck – USC News *
Can hormone replacement therapy protect the heart and brain after menopause?A unique therapy may prevent postmenopausal cardiovascular disease and cognitive decline when taken within six years of menopause
Body Copy *
LOS ANGELES — Many are aware of the short-term symptoms often associated with menopause, such as hot flashes, which are attributed to changes in reproductive hormones. However, they may not know that menopause can put heart and brain health at long-term risk.
Atherosclerosis, the accumulation of plaque in arteries, is a leading cause of death in the U.S., and almost always occurs in women after menopause. Cognitive concerns such as memory loss, dementia and Alzheimer’s disease are dramatically more common in postmenopausal than premenopausal women.
Now, Keck Medicine of USC has launched a clinical trial to study the effect of a novel hormone replacement therapy on postmenopausal cardiovascular disease and cognitive decline.

“Data supports the concept that estrogen, a hormone that the ovaries stop producing after menopause, protects both the heart and brain from damage,” said Howard N. Hodis, MD, director of the USC Atherosclerosis Research Unit, internal medicine specialist with Keck Medicine and lead researcher of the study. “Our study seeks to determine whether estrogen-containing hormone therapy can prevent or slow atherosclerosis progression and cognitive impairment in women after menopause.”

A key aspect of the study is that it is designed for women who are postmenopausal for six years or less.

“We have studied previous data and conducted clinical trials showing that the timing of when a woman starts hormone therapy is crucial,” said Hodis, who is also a professor of medicine and population and public health sciences at the Keck School of Medicine of USC. “There appears to be a limited window of time wherein women benefit from hormone replacement therapy. Beyond six years of menopause, prevention appears to be too late.”

Improving standard hormone replacement therapies

The hormone therapy being studied has been approved by the Food and Drug Administration since 2013 and consists of estrogen paired with a non-hormone drug known as bazedoxifene.
Traditional hormone replacement therapy combines estrogen with progesterone, or more commonly with progestin, a synthetic progesterone. Estrogen alone can cause the lining of the uterus to thicken, causing bleeding and other health issues, which the progesterone or progestin prevents.

However, progestin/progesterone combined with estrogen has been associated with cancer risks. Bazedoxifene prevents the uterine lining from thickening while appearing not to present the same risks, said Hodis.

Trial eligibility and protocols

The clinical trial, titled Advancing Postmenopausal Preventive Therapy, is open to healthy women six years or less post-menopause, who have a uterus, are 45-59 years of age and do not have cardiovascular disease. Upon enrollment, trial participants:

o Receive an ultrasound of their neck artery that is used as a non-invasive baseline measure of atherosclerosis.
o Undergo several tests to gauge their baseline cognitive function and memory.

Every six months, participants have an ultrasound of the neck artery to monitor any progression of atherosclerosis. They also have electrocardiograms to check for different heart conditions, which are done yearly.

At the end of the study, which lasts approximately three years, women retake the cognitive and memory tests so researchers can determine whether there has been any change since enrollment.

The clinical trial is a double-blinded, placebo-controlled trial, meaning neither participants nor the researchers know who is receiving hormone replacement or a placebo. When the clinical trial is completed, researchers will compare results between the therapy and placebo recipients, and participants will be informed which option they received.

So far, some 260 women are participating in the trial; researchers are looking for 100 more women to enroll. Those interested in participating should contact the USC Atherosclerosis Research Unit at (323) 442-2257 or visit aru.usc.edu.

“Our ultimate goal is to help women and their physicians make informed decisions to promote good health post-menopause,” said Hodis.

The trial is funded by the National Institute on Aging (grant R01-AG058691), part of the U.S. National Institutes of Health (NIH).
Donna Shoupe, MD, a reproductive endocrinologist specialist with Keck Medicine and professor of obstetrics and gynecology at the Keck School of Medicine and Wendy J. Mack, PhD, a professor of population and public health sciences with the Keck School of Medicine, are co-investigators of the clinical trial.

The post Can hormone replacement therapy protect the heart and brain after menopause? appeared first on USC News.

Is year-round daylight saving time a good idea? Maybe not


This story was originally published on March 19, 2019.

If the switch to and from daylight saving time has you yawning more than usual, you aren’t alone.

It takes some people a full week to recover from feeling more sluggish than usual after rolling back the clock for daylight saving time. Experts call the phenomenon “social jet lag.”

Much like the jet lag we experience after flying across time zones, losing an hour upsets our circadian rhythm. That not only throws off our sleep schedule but actually has impacts on the cellular level, since many biological functions are timed to that clock.

“It really messes people up,” said Steve Kay, the director of the USC Michelson Center for Convergent Bioscience who is considered one of the preeminent experts in circadian rhythm.

“It affects human performance. The data has been clear in terms of traffic accidents and there’s also data that it’s not great in terms of cardiovascular health: Heart attacks go up.”

In California, daylight saving time could become year-round after voters in November approved Proposition 7. The ballot measure allows the state legislature to make daylight saving time permanent, provided federal law is changed to allow the move.

var pd_tags = new Array;pd_tags[“11066126-src”]=”poll-oembed-simple”;

Research shows there are all kinds of health concerns when it comes to circadian disruption. When experienced long term, as is the case with night shift workers, an individual’s likelihood to develop obesity, Type 2 diabetes or cancer increases, according to USC experts.

OSHA includes daylight saving time side effects in its trainings, since workplace accidents increase by about 6 percent.

Some proponents of the proposition brought up the health concerns, such as upticks in traffic accidents and heart attacks, but USC experts say they’re missing the mark. Permanent daylight saving time wouldn’t solve this issue; instead, it would prolong it — adding more days of social jet lag to the year.

Less light in the a.m. with year-round daylight saving time

There’s a long-held understanding that experiencing light when you first get up is good for you, said USC Assistant Professor Travis Longcore, who researches night lighting. If we could shift our work and school schedules to accommodate the time change we would be fine, he said, but we don’t. That “summer schedule,” during which most of us wake up before the sun, could have real health implications if done long term.

A study on 150,000 nurses found that, over the course of five years, those who worked the night shift had a 30 percent higher chance of developing Type 2 diabetes. If they had other unhealthy habits on top of that, such as smoking, the diabetes risk increased threefold. There’s also research that shows night shift workers are more likely to engage in unhealthy behavior, such as having a poor diet or exercise habits.

Longcore noted a study on four million Americans, comparing how far east they lived in their time zone with cancer rates. People who lived west within their time zones saw impacts: each 20 minutes of later sunrise increased certain cancers by 4 to 12 percent. In California, farther-west San Francisco would be hit harder than L.A., where the sun rises earlier, he said.

Year-round daylight saving time and cellular function

A recent study by Kay and his team showed that circadian disruption changed the way cells function to the point of increasing disease risk, including cancer.

It’s also a change that could disportionately impact teenagers, whose clocks are biologically shifted to wake up later. When they sleep in late on the weekends, it’s not just lethargy — it’s biology, Kay said. That’s the reason some schools are shifting their start times. A study showed students got 34 minutes more sleep, on average, when school started later.

“As we age, our biological clocks shift earlier,” Kay said.

If anything, both Kay and Longcore agree, California should consider switching permanently to standard time, like Hawaii and Arizona. The Society for Research of Biological Rhythms penned a letter to the author of Proposition 7 in support of that. Although it would mean earlier nights, it would address the health implications associated by starting your day in darkness.

“Our highly evolved circadian lifestyle is making us ill,” Kay wrote in a recent paper. “Humans are not evolved for night shifts, nighttime lights and intercontinental travel. Modern life challenges to our circadian system present a long-term threat to our health.”

The post Is year-round daylight saving time a good idea? Maybe not appeared first on USC News.

Pollution paradox: Study finds L.A. residents who drive less are exposed to more air pollution

8201

https://priceschool.usc.edu/news/los-angeles-air-pollution-paradox/
Story Headline and Deck – USC News *
Pollution Paradox: Study finds L.A. residents who drive less are exposed to more air pollution
Body Copy *
Takeaways:
? Regardless of income, areas with a larger share of non-white people experience more air pollution than whiter but otherwise similar areas.

? Decades of racist planning decisions have contributed to inequities in vehicle pollution exposure.

? Various options exist for lessening air pollution and its impact.

Los Angelenos who drive less are exposed to more air pollution, as commuters from predominantly white neighborhoods travel through non-white areas. That’s according to new research co-authored by Geoff Boeing, assistant professor of Urban Planning and Spatial Analysis at the USC Sol Price School of Public Policy.

Those findings, recently published in Urban Studies, demonstrate how decades of racist planning decisions have contributed to a vehicle pollution paradox.

Twentieth-century planners bulldozed urban areas to build freeways for suburban residents to drive to job centers. Although whiter and wealthier areas like Beverly Hills successfully blocked such projects, similar opposition efforts failed in less-white and less-wealthy parts of L.A., such as Boyle Heights, which was carved up by five freeways and two enormous interchanges.

Those decisions reverberate today, allowing Los Angeles residents who travel the most to be exposed to less air pollution, Boeing and his colleagues found. They modeled local exposure to vehicular air pollution as a function of vehicle kilometers traveled, using demographic, household travel, street network design and air pollution data.

The study concluded that:

? All else equal, census tracts whose residents drive less are exposed to more vehicular air pollution. (Census tracts are subdivisions of a county, each of which averages about 4,000 people.)

? Regardless of income, tracts with a larger share of non-white people experience more air pollution than whiter but otherwise similar tracts.

? On average, white commuters travel through tracts that are far more non-white than tracts where most white commuters live. Yet this disparity does not exist in the opposite direction, as non-white commuters, on average, don’t travel through tracts that are substantially whiter than their home tracts.

Boeing noted that previous research showed that communities of color tend to be exposed to more air pollution. However, earlier studies often focused on their proximity to pollution sources but didn’t control for how much pollution those communities were generating themselves. For this study, Boeing sought to measure emissions from mobile sources — vehicles — and control for how much pollution was generated by the communities he examined.

The results — that the more L.A. residents drive, the less they’re exposed to air pollution — were “superficially surprising,” Boeing said. “But given what we know about L.A. geography, we expect to find this kind of injustice in the city. You get these paradoxes of unfairness.”

Righting the wrongs of past urban planning decisions

The study’s authors, including USC Price School PhD candidate Clemens Pilgram and USC Price School graduate Yougeng Lu, proposed a handful of policy fixes. None of them can single-handedly undo decades of systematic urban planning, Boeing noted. Still, some possible solutions are:

? Raise fuel efficiency standards for new cars and encourage electrification. That could reduce emissions without cutting the amount of driving. However, that would not eliminate air pollution from rubber tires and brake dust.

? Enact tolls or other forms of congestion taxes to reduce driving or generate compensation for its negative side effects.

? Discourage commuting altogether by incentivizing more people to work from home, perhaps through tax credits.

? Address environmental injustice through the housing market. Policymakers could permit more residential construction in job-rich neighborhoods, thereby reducing commute distances. They could also legalize construction of denser and more affordable housing in less-polluted, exclusive neighborhoods to reduce exposure disparities.

The research findings are similar to other stories of environmental injustice, Boeing said. “The story is, basically, that people with more privilege and more wealth are usually able to export their pollution into other communities.”

The post Pollution paradox: Study finds L.A. residents who drive less are exposed to more air pollution appeared first on USC News.

Eli Lilly is cutting insulin prices and capping copays at $35: 5 questions answered

Eli Lilly is cutting insulin prices and capping copays at $35 – 5 questions answered
Published: March 3, 2023 2.39pm EST
Authors

Dana Goldman
Dean of the Sol Price School of Public Policy; Professor of Pharmacy, Public Policy, and Economics, University of Southern California

Karen Van Nuys
Executive Director of the Value of Life Sciences Innovation program; Fellow at the USC Schaeffer Center, University of Southern California

Disclosure statement

Dr. Goldman’s research is supported by the Schaeffer Center at the University of Southern California, which is in turn supported by gifts and grants from public and private sources. More detail is available in the Schaeffer Center annual report here: https://healthpolicy.usc.edu/report/2021-schaeffer-center-annual-report/
Karen Van Nuys is an employee of the Schaeffer Center at the University of Southern California. The Schaeffer Center is supported by gifts and grants from public and private sources; more detail is available in the Schaeffer Center annual report here: https://healthpolicy.usc.edu/report/2021-schaeffer-center-annual-report/
Partners

University of Southern California

University of Southern California provides funding as a member of The Conversation US.

View all partners

CC BY ND
We believe in the free flow of information
Republish our articles for free, online or in print, under a Creative Commons license.

Republish this article
Email
Twitter11
Facebook49
LinkedIn
Print
Pharmaceutical giant Eli Lilly is slashing the list prices for some of its most popular insulin products by 70% and capping insulin copays at US$35 for uninsured patients and those with private health insurance. These changes follow efforts by the federal government, the California state government, nonprofits and some companies to make insulin more affordable for the more than 7 million Americans with diabetes who require it.

The Conversation asked Dana Goldman and Karen Van Nuys, two scholars who have researched insulin pricing, to explain why Eli Lilly is dramatically cutting the cost of some of its insulin products and to sum up how it may improve access to this essential medical treatment.

1. Why is Lilly reducing prices now?

High insulin prices have not earned any U.S. manufacturer many friends, with list prices increasing 54% from 2014 to 2019.

Most troublingly, an estimated 1.3 million uninsured people with diabetes and patients with inadequate insurance have resorted to rationing their insulin. Skipping doses because of high insulin prices has sometimes had tragic and even deadly consequences.

Read news coverage based on evidence, not tweets

Get newsletter
But growing competition has shaken up the insulin market in recent years.

For example, Walmart introduced its own private-brand insulin in 2021. Mylan, a large generic drugmaker, developed a version of long-acting insulin called Semglee, priced 65% lower than its branded competitor. But few consumers use those products.

Efforts to produce cheaper insulin by the nonprofit drugmaker CivicaRx and the state of California are several years out and won’t provide immediate relief.

Then there’s the Inflation Reduction Act, a big spending package Congress approved in 2022. It capped insulin out-of-pocket costs at $35 for Americans with Medicare, a government health insurance program that covers people over 65.

And, in fact, Lilly itself has been trying to disrupt insulin prices. In 2019, the drugmaker introduced insulin lispro, a lower-cost version of its blockbuster insulin, Humalog.

2. What does this mean for Americans who need insulin?

Part of the problem with the existing system is that some patients, especially if they’re uninsured or have high deductibles, end up paying the list price – which can mean spending $1,000 or more a month on insulin. This can be a crushing financial burden.

Lilly’s new $35 out-of-pocket cap means that privately insured patients and those without insurance requiring insulin will spend no more than that monthly for copays. Its 70% reduction in the list price of two popular name brand insulins, Humalog and Humulin, will bring some financial relief. And the company has also reduced its generic lispro’s list price to $25 a vial, down from $126.

The evidence is clear that these price reductions will improve patient adherence – which means fewer missed doses of this lifesaving medication.

3. How might Lilly’s actions affect the whole industry?

Lilly has put pressure on its biggest competitors, Novo Nordisk and Sanofi, to follow suit.

These lower prices could also make Lilly’s insulins affordable to cash-paying patients. As a result, these insulins could be added to the list of drugs provided by pharmacies that are disrupting the U.S. prescription drug industry, like Mark Cuban’s Cost Plus Drug Co. and Blueberry Pharmacy. These companies provide low-cost drugs with transparent markups or through membership programs, typically without insurance.

4. Why did insulin get so expensive in the US?

That lispro, Lilly’s own, cheaper authorized generic insulin, hasn’t completely displaced the equivalent name brand Humalog in the market by now may seem surprising. But it is the result of the complex U.S. prescription drug distribution system.

Insulin prices are the result of a complex set of negotiations between manufacturers and pharmacy benefit managers, which act on behalf of insurers. The three largest – CVS Caremark, Express Scripts and Optum Rx – handle about 80% of all prescriptions.

These middlemen negotiate directly with Lilly and other insulin manufacturers, focusing on two key sums: the list price and the rebate. Manufacturers are paid the list price but then must pay a rebate to the pharmacy benefit managers.

How do pharmacy benefit managers get manufacturers to pay rebates? They maintain formularies – lists of drugs that patients in a health plan can access. If an insulin manufacturer wants to supply diabetes patients, it needs to remain on those formularies. And doing so requires the manufacturer to pay bigger rebates. Otherwise, pharmacy benefit managers can exclude the manufacturer.

In 2016, OptumRx, which negotiates insulin prices for about 28 million people, excluded only four types of insulin from its formulary. By 2022, OptumRx was excluding 13 insulins.

Keeping insulin on formularies, in short, has required high rebates, and list prices have increased along with them. Ironically, as insulin list prices have been rising, manufacturers have been making less money off of insulin sales, while middlemen have been making more. The key to true price competition is to ensure access to all versions of insulin and to convince patients and providers that people with diabetes can substitute lower-cost versions without compromising their health.

5. What might happen next?

The Federal Trade Commission, a government agency that probes anti-competitive practices, and Congress are now investigating pharmacy benefit managers’ rebate and formulary practices, among other things. These investigations, along with Lilly’s moves, may lead other insulin manufacturers to lower their list prices.

And once its competitors decide whether they will follow Lilly’s example, pharmacy benefit managers will be under a lot of scrutiny to see whether they give preferred formulary placement to the lowest-cost insulin products, or to those that pay the highest rebates.

The post Eli Lilly is cutting insulin prices and capping copays at $35: 5 questions answered appeared first on USC News.

Keck Medicine of USC names Ikenna ‘Ike’ Mmeje president and CEO of USC Arcadia Hospital

8203 website *
https://news.keckmedicine.org/keck-medicine-of-usc-names-ikenna-ike-mmeje-president-and-ceo-of-usc-arcadia-hospital/
Story Headline and Deck – USC News *
Keck Medicine of USC names Ikenna (Ike) Mmeje president and CEO of USC Arcadia Hospital
The seasoned health care executive will lead the longstanding community hospital and recent addition to the Keck Medicine health system
Body Copy *
LOS ANGELES — Keck Medicine of USC has named Ikenna (Ike) Mmeje president and CEO of USC Arcadia Hospital (USC-AH), effective March 13.
In this position, Mmeje will further the health system’s mission to expand access to specialized health care and research to the San Gabriel Valley and beyond. He will oversee all management and operations of the hospital, including corporate compliance, strategic plan implementation and fundraising.
“Mmeje will utilize his wealth of knowledge and experience running complex, high-performing hospitals in his new role leading USC Arcadia Hospital,” said Rod Hanners, CEO of Keck Medicine.
Mmeje replaces current USC-AH president and CEO Dan Ausman, who is retiring after a long and successful career in health care, including 12 years with USC-AH.
“I am humbled and excited to join USC Arcadia Hospital,” said Mmeje. “The hospital has a rich 120-year history of caring for patients and the community, and I look forward to advancing its legacy and mission far into the future.”
Prior to joining Keck Medicine, Mmeje served as chief operating officer (COO) of both MemorialCare Long Beach Medical Center and Miller Children’s & Women’s Hospital Long Beach. Previously, he held CEO and COO roles with Tenet Healthcare.
Mmeje is active on a number of boards, committees and organizations, including the American College of Healthcare Executives and the National Association of Health Services Executives, and is a Fellow of the American College of Healthcare Executives.
He holds a Bachelor of Arts in public health and social welfare from the University of California, Berkeley and a Master of Health Services Administration from the University of Michigan.
USC-AH, founded in 1903, affiliated with Keck Medicine in July 2022. It is a full-service community hospital offering advanced cardiovascular services. Los Angeles County has designated the hospital as both a heart attack receiving center and a comprehensive stroke center, as well as an Emergency Department Approved for Pediatrics. The hospital also offers a variety of surgical services in orthopaedics, neurosurgery, obstetrics, gynecology, and cancer care, plus physical rehabilitation and many other medical specialties.
###

The post Keck Medicine of USC names Ikenna ‘Ike’ Mmeje president and CEO of USC Arcadia Hospital appeared first on USC News.

Toward the cancer solution we need: Experts from science, engineering and the humanities join together

8183

https://dornsife.usc.edu/news/stories/3819/cancer-solution-we-need/
Story Headline and Deck – USC News *
The cancer solution we need: uniting experts from science, engineering and the humanities

Scientists from USC Dornsife and Cedars-Sinai rally scholars around the country and in diverse fields to find better ways of beating cancer.
Body Copy *
Could a virtual cancer center that unites experts throughout the nation in fields as diverse as physics, molecular biology and art be the key to advancing cancer treatments and ultimately a cure?

The USC Dornsife scientist who co-leads the new Convergent Science Virtual Cancer Center (CSVCC), which recently held its first workshop for participating members, is more than a little enthusiastic about its potential. And as a Dean’s professor of biological sciences, aerospace and mechanical engineering, urology, medicine, and biomedical engineering, Peter Kuhn knows a little something about the power of convergent expertise to solve big challenges.

Kuhn says the CSVCC is enabling the future of science and a national expansion of the Convergent Science Institute in Cancer, which he directs at the USC Michelson Center for Convergent Bioscience.

With funding from the U.S. Department of Defense (DOD) through the Congressionally Directed Medical Research Programs’ Peer Reviewed Cancer Research Program, he co-founded the CSVCC with Dan Theodorescu, director of Cedars-Sinai Cancer.

“Dan and I have been discussing both convergent science and the future of science in general for a while, and this visionary call for proposals by the Department of Defense was the perfect opportunity to put it all together,” said Kuhn. “We focus on mentoring junior faculty members from institutions across the nation, helping them become the next generation of leaders and ‘convergent science practitioners.'”

The center’s first conference last fall provided an opportunity for center scholars, members of the convergent science council and program officials to meet at USC to share and further develop their ideas for tackling cancer. The initial group of eight scholars spent two days with the council members and the center’s leadership to discuss new collaborative projects, opportunities and challenges in convergent science career development, and bringing additional scholars on board. The center expects to welcome a new cohort of scholars this summer.

Other topics discussed include the use of artificial intelligence to study, diagnose and treat cancer, how best to move discoveries from the lab to the clinic, and the advancement of researchers’ professional development.

Why is Kuhn so confident in the power of convergent science as where diverse experts are working together on wicked problems like cancer? He says that many breakthroughs in science projects stem from chance encounters between scholars with deep and disparate expertise who realize they can work together on a common puzzle, each from their unique angle. The center, however, doesn’t rely on chance; it brings experts together with intention, he says.

“Seeing how after just one year the scholars are already collaborating with one another and confidently talk about each other’s science in the larger context, it’s clear to me that we’re on the right track, that convergent science can be purposeful and by design,” he said.

Kuhn and Theodorescu hope to expand the center, adding more scholars from around the nation to spark even more collaborative projects.

“We started this experiment at USC just eight years ago and are now connecting some of the most talented emerging scholars in cancer research from around the country through this DOD-supported effort,” said Kuhn, “but there’s the potential for us to do so much more.”

The post Toward the cancer solution we need: Experts from science, engineering and the humanities join together appeared first on USC News.

Largest known genetic study of prostate cancer in men of African descent could improve screening

The largest known genetic study of prostate cancer in men of African descent has revealed nine new genetic variants that increase the risk of prostate cancer in the understudied population, including a genetic risk score linked to aggressive forms of the disease.

The meta-analysis, led by researchers at the Keck School of Medicine of USC, included data from 10 genome-wide association studies–virtually all of the existing data on genetic risk for prostate cancer in men of African ancestry. That includes data collected in the United States, Africa and the Caribbean on 19,378 men with prostate cancer who were compared to a control group of 61,620 healthy men.

“The ability to differentiate between the risk for aggressive and non-aggressive forms of the disease is of critical importance,” said Christopher Haiman, ScD, AFLAC Chair in Cancer Research at the USC Norris Comprehensive Cancer Center and senior author of the study. “Until now, risk scores haven’t been able to do that.”

These findings, out today in European Urology, can be used to refine polygenic risk scores, tools that assess a person’s risk for a condition based on the combined influence of multiple genetic factors. The researchers said that more accurate polygenic risk scores for men of African descent could help in identifying high-risk patients early on.

“Prostate cancer survival is significantly lower among men diagnosed with aggressive disease,” said Fei Chen, PhD, an assistant professor of clinical population and public health sciences at the Keck School of Medicine and the study’s first author. “Our findings suggest that these polygenic risk scores could be useful for identifying men who may benefit from earlier and more frequent screenings.”

Prostate cancer takes a greater toll on Black men than on men of other races. In the United States, 1 in 6 Black men will get prostate cancer in their lifetime, compared to 1 in 8 men overall. Black men are also more than twice as likely to die from the disease.

While past studies have linked nearly 270 genetic variants to prostate cancer risk, researchers have yet to find a clear explanation for the disproportionate risk among men of African ancestry. Genetic research thus far has also failed to predict which men face a high risk for aggressive prostate cancer, versus those who may get less deadly forms of the disease.

The new study is beginning to address those questions. Researchers identified nine new genetic risk factors for prostate cancer, seven of which are found either largely or exclusively in men of African ancestry. For the first time, researchers also found that genetic differences can signal which men are most likely to develop aggressive prostate cancer.

For instance, one variant in the 8q24 human chromosomal region, long known to influence prostate cancer risk, is only found in men of African ancestry.

“This particular variant is influencing the risk of aggressive disease in this population,” said Haiman, who also co-leads the USC Norris Cancer Epidemiology Program and directs the Center for Genetic Epidemiology at the Keck School of Medicine.

Better screening for prostate cancer

The newly identified variants can be incorporated into genetic tests that help patients understand their cancer risk and decide how early and often to get screened, Haiman said.

Through the RESPOND initiative, funded by the National Institutes of Health and the Prostate Cancer Foundation (PCF), he and his colleagues are continuing to study the disease among African American men, including how social determinants, access to care and other factors affect prostate cancer recurrence, progression and survival rates. One of their long-term goals is to develop a widely available genetic screening test that can help men of all ages assess their risk levels.

“Through the Robert F. Smith-PCF Special Challenge Award for the Smith Polygenic Risk Test, the Prostate Cancer Foundation is proud to invest in the critical work of the RESPOND investigators to understand and address the reasons why African American men disproportionally experience aggressive prostate cancer, and ultimately advance our shared mission to end death and suffering from this disease,” said PCF Executive Vice President and Chief Science Officer Howard R. Soule, PhD.

Earlier research by Haiman’s team identified many genetic risk factors for prostate cancer and offered early insights on risk among men of African ancestry. Evidence of risk factors specific to this population points to the importance of continuing to collect data from diverse groups, including men of African, Asian and Hispanic descent.

“The vast majority of studies to date have been conducted in populations of European ancestry, which creates a huge bias in our understanding of genetic risk for disease,” Haiman said.

About this study

In addition to Haiman and Chen, the study’s other authors are David V. Conti, Burcu F. Darst, Alisha Chou, Xin Sheng, Anqi Wang, Jiayi Shen, Sue A. Ingles, Suhn K. Rhie, Mariana C. Stern, Susan M. Gundell, Peggy Wan and John D. Carpten of the Departments of Population and Public Health Sciences, Biochemistry and Molecular Medicine, and Translational Genomics, Keck School of Medicine of USC; Ravi K. Madduri and Alex A. Rodriguez of Argonne National Laboratory, Edward J. Saunders, Zsofia Kote-Jarai and Koveela Govindasami of the Institute of Cancer Research, London; Jeannette T. Bensen of the University of North Carolina at Chapel Hill; Rick A. Kittles of City of Hope Comprehensive Cancer Center; Sara S. Strom and Chad D. Huff of the University of Texas M.D. Anderson Cancer Center; Benjamin A. Rybicki and Christine M. Neslund-Dudas of Henry Ford Hospital; Barbara Nemesure and Anselm J. Hennis of Stony Brook University; William B. Isaacs of the James Buchanan Brady Urological Institute, Johns Hopkins Hospital and Medical Institution; Janet L. Stanford of the Fred Hutchinson Cancer Research Center; Wei Zheng, Melinda C. Aldrich and Todd L. Edwards of Vanderbilt University Medical Center; Maureen Sanderson of Meharry Medical College; Esther M. John and Ann W. Hsing of Stanford University School of Medicine; Jong Y. Park, Thomas A. Sellers and Kosj Yamoah of the Moffitt Cancer Center; Jianfeng Xu of the NorthShore University HealthSystem; Ying Wang and Alpa V. Patel of the American Cancer Society; Sonja I. Berndt, Wei Tang, Michael B. Cook, Stefan Ambs and Stephen J. Chanock of the National Cancer Institute; Edward D. Yeboah and Andrew A. Adjei of the University of Ghana Medical School; Yao Tettey of the University of Ghana and Korle Bu Teaching Hospital; Joseph Lachance of Georgia Institute of Technology; Christopher T. Rentsch of the Yale School of Medicine, the VA Connecticut Healthcare System and the London School of Hygiene & Tropical Medicine; Kelly Cho of Brigham and Women’s Hospital, Harvard Medical School and the VA Boston Healthcare System; Benjamin H. Mcmahon of Los Alamos National Lab; Richard B. Biritwum, Evelyn Tay, Afua Darkwa-Abrahams and James E. Mensah of Korle Bu Teaching Hospital; Ann Truelove and Shelley Niwa of Westat; Adam B. Murphy of Northwestern University; Dana C. Crawford , William S. Bush of the Cleveland Institute for Computational Biology, Case Western Reserve University; Olivier Cussenot of Sorbonne Universite and CeRePP, Tenon Hospital, Paris; Gyorgy Petrovics and Jennifer Cullen of Uniformed Services University of the Health Sciences; Anand P. Chokkalingam of the University of California, Berkeley; Phyllis J. Goodman of the Fred Hutchinson Cancer Research Center; Thomas J. Hoffmann of the University of California, San Francisco; Bettina F. Drake of Washington University School of Medicine; Jennifer J. Hu of University of Miami School of Medicine; Jacob M. Keaton of Vanderbilt University Medical Center and the National Human Genome Research Institute, National Institutes of Health; Jacklyn N. Hellwege of Vanderbilt University Medical Center and Vanderbilt Genetics Institute; Peter E. Clark of Atrium Health/Levine Cancer Institute; Mohamed Jalloh, Serigne M. Gueye and Lamine Niang of Hopital General Idrissa Pouye, Dakar, Senegal; Olufemi Ogunbiyi, Michael O. Idowu, Olufemi Popoola and Akindele O. Adebiyi of the University of Ibadan and University College Hospital, Ibadan, Nigeria; Oseremen I. Aisuodionoe-Shadrach, Hafees O. Ajibola, Mustapha A. Jamda, Olabode P. Oluwole and Maxwell Nwegbu of the University of Abuja, University of Abuja Teaching Hospital and Cancer Science Center, Abuja, Nigeria; Ben Adusei and Sunny Mante of 37 Military Hospital, Accra, Ghana; Halimatou Diop of Hopital Aristide Le Dantec, Dakar, Senegal; Stephen K. Van Den Eeden of Kaiser Permanente, Northern California and the University of California, San Francisco; Pascal Blanchet and Laurent Brureau of Univ Antilles, Univ Rennes, Inserm, EHESP, Irset, Pointe-a-Pitre, Guadeloupe, France; Jay H. Fowke of the University of Tennessee Health Science Center; Graham Casey of the University of Virginia; Alexander Lubwama and Stephen Watya of Uro Care, Kampala, Uganda; Ian M. Thompson Jr. of CHRISTUS Santa Rosa Medical Center Hospital; Robin Leach of University of Texas Health Science Center at San Antonio; Douglas F. Easton of Centre for Cancer Genetic Epidemiology, University of Cambridge; Michael H. Preuss and Ruth J. Loos of the Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai; James L. Mohler of the University of North Carolina at Chapel Hill and Roswell Park Cancer Institute; Elizabeth T. Fontham of Louisiana State University Health Sciences Center; Gary J. Smith of Roswell Park Cancer Institute; Jack A. Taylor of the National Institute of Environmental Health Sciences; Shiv Srivastava of Georgetown University Medical Center; Rosaline A. Eeles of the Institute of Cancer Research, London, and Royal Marsden NHS Foundation Trust; Adam S. Kibel of Brigham and Women’s Hospital, Harvard Medical School; Luc Multigner of Univ Rennes, Inserm, EHESP, Irset, Rennes, France; Marie-Elise Parent of Centre Armand-Frappier Sante Biotechnologie, Institut national de la recherche scientifique, Laval, QC, Canada; Florence Menegaux of INSERM, University Paris-Sud, University Paris-Saclay, and Paris-Sud University, Villejuif Cedex, France; Geraldine Cancel-Tassin of Sorbonne Universite and CeRePP, Tenon Hospital, Paris, France; Eric A. Klein of Cleveland Clinic Lerner Research Institute; Caroline Andrews of Harvard TH Chan School of Public Health and Division of Population Sciences, Dana Farber Cancer Institute and Glickman Urological & Kidney Institute; Timothy R. Rebbeck of Harvard TH Chan School of Public Health and Division of Population Sciences, Dana Farber Cancer Institute; John S. Witte of Stanford Canter Institute, Stanford University and Kaiser Permanente, Northern California; William J. Blot Vanderbilt University Medical Center and the International Epidemiology Institute; J. Michael Gaziano of Brigham and Women’s Hospital, Harvard Medical School and VA Boston Healthcare System; and Amy C. Justice of Yale School of Medicine and the VA Connecticut Healthcare System.

This work was supported by the National Cancer Institute at the National Institutes of Health [U19CA148537, U19CA214253, R01CA257328, T32CA229110]; the Prostate Cancer Foundation [20CHAS03]; and the Million Veteran Program [MVP017].

# # #

(Photo/iStock)

 

 

 

 

Find USC on ImageImageImageImageImageImage

Edit email | Unsubscribe

Need an expert?
Pressroom.usc.edu
(213) 740-2215

 

 

 

The post Largest known genetic study of prostate cancer in men of African descent could improve screening appeared first on USC News.

In memoriam: Allen W. Mathies, 92, former Keck School of Medicine of USC dean

8191

from submitter) Janice O’Leary
Is this story embargoed? *
No
URL of story on your school/unit website *
https://keck.usc.edu/allen-w-mathies-md-phd-dedicated-trojan-and-former-keck-school-of-medicine-dean-dies-at-92/
Story Headline and Deck – USC News *

Allen W. Mathies, MD, PhD, Dedicated Trojan and Former Keck School of Medicine Dean Dies at 92
Body Copy *
The Keck School of Medicine community mourns the February 5 death of Allen W. Mathies, MD, PhD, who served as dean of the medical school from 1975 to 1985. In 1999, he was named Dean Emeritus of Keck School of Medicine of USC. He was 92.

During his tenure, he oversaw some of the Keck School’s most significant years of growth, including the building of the Norris Comprehensive Cancer Center, the doubling of the number of faculty, substantially increasing the school’s endowment, and making the decision to build and operate a university hospital.

“That represented a 180-degree turn for USC,” he said in an interview for the USC Living History Project in 2007, taking responsibility for a hospital rather than partnering with Los Angeles County, as had been the model for the LAC+USC Hospital relationship. “It would put us so far ahead with research and translational science,” he said.

“He felt strongly about this decision,” his wife, Weta, recalled in an interview. “He felt the faculty needed a place where they could also see private patients.”

During his time as dean, he helped change the character of the school, a shift he says began with his predecessors, Franz Bauer, MD, Roger Egeberg, MD, and Clayton Loosli, MD, PhD, who wanted to see it move from a school that trained physicians to practice, to one that also encouraged scientific investigation. It was Dean Bauer who first named Mathies to an administrative post, as associate dean of the medical school.

During his 2007 Living History interview, Mathies told the story of when he questioned Bauer, “What does an associate dean do?” And Bauer answered, “You do whatever I want you to do. And when I’m not here, you act as dean.” He found himself participating in the recruitment of faculty, allocating budgets and space. “It was a wonderful apprenticeship,” he said.

It’s no surprise that Mathies was as passionate about research as he was the practice of medicine. After growing up in Colorado and doing his undergraduate work at Colorado College, he served as an Army hospital lab technician at Fort McClellan, Ala, and then earned a master’s degree and PhD in parasitology from Columbia University. He ultimately sought to understand both the organism and the host, which led him to pursue a medical degree, which he received, cum laude, from the University of Vermont College of Medicine in 1961.

He came to USC as an intern and then a resident in pediatrics. In 1963, he was appointed senior lecturer in biological sciences at USC and then was named an assistant professor of pediatrics in 1964. He served as the head of the communicable disease service at LA County Hospital. He saw a diphtheria epidemic grip the city, and treated cases of meningitis, typhoid, tuberculosis. He witnessed the rollout of new classes of antibiotics and vaccinations. “It was a glorious time to be engaged in that kind of activity,” he said in his 2007 interview.

After 10 years as dean, Mathies left USC in 1985 and became the chief executive officer and president of Huntington Hospital. He helped shape that institution’s future, beginning with outlining a master plan and then building a new hospital. Upon his retirement 1995, he became president emeritus and a member of the board of directors, where he served until his last day.

Mathies continued his affiliation with USC as an Emeritus Member of the USC Board of Councilors and a member of the Institutional Biosafety Committee, helping to ensure the safety of laboratory technicians and scientists as they worked with gene transfers and viruses. In his 2007 interview, Mathies spoke of his relationship with USC with genuine fondness, “It’s been a wonderful association, and I’ve enjoyed every minute of it.”

“He loved his time at USC,” said Weta. “He was very proud of his time there. And of course, he loved USC football. We had season tickets.”

Mathies is survived by Weta, his beloved wife of 67 years, their two sons, John and Bill (Lisa), his sister Margaret (Ed), his granddaughters, Amanda (Jack) and Riley (Mark), and his great-granddaughter, Georgia. Donations can be made in Mathies’ memory to the Keck School of Medicine.

The post In memoriam: Allen W. Mathies, 92, former Keck School of Medicine of USC dean appeared first on USC News.